Levodopa + Carbidopa Labesfal (Carbidopa, Levodopa)

Levodopa serves as a precursor that is converted into dopamine within the central nervous system, while carbidopa inhibits the peripheral enzyme aromatic L‑amino acid decarboxylase. This inhibition prevents premature conversion of levodopa outside the brain, increasing its availability where it is needed and reducing peripheral side effects.

The specific dose and dosing schedule are determined by the prescribing clinician based on the individual patient's condition, response, and tolerability. Dosage adjustments are made during treatment to achieve optimal symptom control while minimizing adverse effects.

The safety of levodopa/carbidopa during pregnancy or lactation has not been definitively established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Levodopa + Carbidopa is considered the most effective symptomatic therapy for Parkinson's disease because it directly replenishes dopamine. Other agents, such as dopamine agonists or MAO‑B inhibitors, may be used as adjuncts or early‑stage options, but they generally provide less robust motor improvement than the levodopa/carbidopa combination.

Store the product at ambient temperature, below 25 °C, in the original packaging. Keep it away from moisture, excessive heat, and direct sunlight to maintain stability and potency throughout its shelf life.

The medication is taken orally, usually with a glass of water. It may be taken with or without food, but consistent timing with meals can help reduce gastrointestinal side effects. Patients should follow the prescriber's instructions regarding frequency and timing of each dose.

Serious risks include the development of dyskinesias (involuntary movements), psychosis or hallucinations, severe orthostatic hypotension, and rare allergic reactions such as anaphylaxis. Patients should be monitored regularly for these events, and any concerning symptoms should be reported to a healthcare professional promptly.

Patients with known hypersensitivity to levodopa, carbidopa, or any excipients in the formulation should avoid the product. It is also contraindicated in individuals with narrow‑angle glaucoma or those taking non‑selective MAO inhibitors. A thorough medical history should be reviewed before initiating therapy.